Damilola Samuel Bodun

Damilola Samuel Bodun

Auto-generated profile, based on publicly available information

Damilola Samuel Bodun


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2023 in Computational Biology and Chemistry
Verified
Journal Article
Closed access
DBDamilola S. Bodun
Damilola S. Bodun
DODamilola A. Omoboyowa
Damilola A. Omoboyowa
OOOlaposi I. Omotuyi
Olaposi I. Omotuyi
EOEzekiel A. Olugbogi
Ezekiel A. Olugbogi
TBToheeb A. Balogun
Toheeb A. Balogun
EOEmmanuel S. Omirin
Emmanuel S. Omirin

25 December 2021 in Biology Methods and Protocols
Verified
Journal Article
Open access
PDF file
DODamilola Omoboyowa
Damilola Omoboyowa
TBToheeb Balogun
Toheeb Balogun
OSOluwatosin A Saibu
Oluwatosin A Saibu
ODOnyeka S. san diego
Onyeka S. san diego
AAAbdullahi Alausa
Abdullahi Alausa
SMSekinat O Musa
Sekinat O Musa
Prostate cancer (PCa) is the most common malignancy found in men and the second leading cause of cancer-related death worldwide. Castration-resistant PCa (CRPC) is defined by PCa cells that stop responding to hormone therapy. Cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17A1) plays a critical role in the biosynthesis of androgens in humans. Androgen signaling cascade is a principal survival pathway for PCa cells and androgen-deprivation therapy (ADT) remains the key treatment for patients marked with locally advanced and metastatic PCa cells. Available synthetic drugs have been reported for toxicity, drug resistance, and decreasing efficacy. Thus, the design of novel selective inhibitors of CYP17A1 lyase would help circumvent associated side effects and improve pharmacological activities. Therefore, we employed structural bioinformatics techniques via molecular docking; molecular mechanics generalized born surface area (MM-GBSA), molecular dynamics (MD) simulation, and pharmacokinetic study to identify putative CYP17A1 lyase inhibitors. The results of the computational investigation showed that the Prunus dulcis compounds exhibited higher binding energy than the clinically approved abiraterone acetate. The stability of the ligand with the highest binding affinity (quercetin-3-o-rutinoside) was observed during MD simulation for 10 ns. Quercetin-3-o-rutinoside was observed to be stable within the active site of CYP17A1Lyase throughout the simulation period. The result of the pharmacokinetic study revealed that these compounds are promising therapeutic agents. Collectively, this study proposed that bioactive compounds from P. dulcis may be potential selective inhibitors of CYP17A1Lyase in CRPC treatments.

21 March 2023 in Informatics in Medicine Unlocked
Verified
Journal Article
Open access
DODamilola Omoboyowa
Damilola Omoboyowa
DBDamilola S. Bodun
Damilola S. Bodun
JSJamiyu A. Saliu
Jamiyu A. Saliu

19 December 2024 in Journal of Computational Biophysics and Chemistry
Verified
Journal Article
Closed access
DBDamilola Samuel Bodun
Damilola Samuel Bodun
AAAdeniyi Ayinde Abdulwahab
Adeniyi Ayinde Abdulwahab
TATemitope Ibukunoluwa Adegbenro
Temitope Ibukunoluwa Adegbenro
ECEmidun Olayinka Chidinma
Emidun Olayinka Chidinma
SOSamuel Aduramurewa Osunnaya
Samuel Aduramurewa Osunnaya
RARachael Oluwakamiye Abolade
Rachael Oluwakamiye Abolade

27 June 2025 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
DBDamilola Samuel Bodun
Damilola Samuel Bodun
IIIsiaka O. Ibrahim
Isiaka O. Ibrahim
MBMujeebat Bashiru
Mujeebat Bashiru
RARachael Oluwakamiye Abolade
Rachael Oluwakamiye Abolade
WNWilberforce K. Ndarawit
Wilberforce K. Ndarawit
OAOlayinka O. Ajani
Olayinka O. Ajani

4 October 2023 in Informatics in Medicine Unlocked
Verified
Journal Article
Open access
SSSalimat O. Sofela
Salimat O. Sofela
DBDamilola S. Bodun
Damilola S. Bodun
DODamilola A. Omoboyowa
Damilola A. Omoboyowa
PAPrecious A. Ajiboro
Precious A. Ajiboro
DNDaniel O. Nwankwo
Daniel O. Nwankwo
IAIfetayo H. Ajayi
Ifetayo H. Ajayi